Monograph
S01BC11 - Bromfenac |
Not porphyrinogenic |
NP |
Rationale
Bromfenac is administered locally in the eye and plasma concentrations are not quantifiable. The hepatic exposure is insignificant
Chemical description
Benzophenone
Therapeutic characteristics
Bromfenac is an anti-inflammatory agent used in the treatment of postoperative ocular inflammation following cataract extraction in adults. One drop is administered in the eye twice daily in two weeks after cataract extraction (SPC).
Hepatic exposure
Bromfenac has not been detected in plasma after ocular administration (SPC).
Metabolism and pharmacokinetics
In vitro studies indicate that bromfenac is metabolized by CYP2C9 (SPC).
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Yellox.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024